Latest

Learn how antibiotic-resistant UTI testing identifies ESBL, CRE, resistance genes, and antibiotic susceptibility, and how culture results guide treatment and follow-up.

Antibiotic-Resistant UTI Test: ESBL, CRE, Resistance Markers, and Culture Meaning

Learn what asymptomatic bacteriuria means, how a positive urine culture without UTI symptoms is interpreted, and when screening, treatment, or follow-up matters.

Asymptomatic Bacteriuria Test: Positive Culture Without Symptoms and When It Matters

Learn how bacteria in urine are interpreted using urinalysis, culture, colony count, symptoms, and sample quality, including when contamination or follow-up testing matters.

Bacteria in Urine Test: UTI, Contamination, Colony Count, and Culture Follow-Up

Learn how a catheter urine culture helps diagnose catheter-associated UTI, how samples are collected, and what colony counts, pyuria, resistance, and positive results mean.

Catheter Urine Culture Test: Catheter-Associated UTI and Culture Meaning

Learn how a chlamydia and gonorrhea urine NAAT works, how to collect first-catch urine, what positive or negative results mean, and when follow-up testing is needed.

Chlamydia and Gonorrhea Urine NAAT Test: STI Screening, Positive Result, and Meaning

Learn how to collect a clean-catch urine culture, reduce contamination, handle the sample correctly, and understand mixed flora, colony counts, repeat testing, and accurate results.

Clean-Catch Urine Culture Test: Sample Collection, Contamination, and Accurate Results

Diagnostics

Home Diagnostics Page 86

Understand comprehensive genomic profiling results, tissue and liquid testing, actionable mutations, MSI, TMB, possible germline findings, limitations, and treatment matches.

Comprehensive Genomic Profiling Test: Cancer Genes, Mutations, and Results

Understand DICER1 genetic test results, pleuropulmonary blastoma and other tumor risks, mosaicism, childhood and adult surveillance, inheritance, and family testing.

DICER1 Genetic Test: Tumor Predisposition, Cancer Risk, and Results

Learn how a DNMT3A mutation test is used in AML and clonal hematopoiesis, what variant allele frequency means, and how positive, negative, and persistent results are interpreted.

DNMT3A Mutation Test: AML, Clonal Hematopoiesis, and Results

Understand EGFR mutation testing for lung cancer, including tissue and plasma methods, exon 19, L858R and exon 20 results, targeted therapy meaning, resistance, and next steps.

EGFR Mutation Test: Lung Cancer, Targeted Therapy, and Results

Learn how EPCAM deletion testing identifies a cause of Lynch syndrome, why deletion analysis matters, what positive and negative results mean, and how findings affect colon cancer surveillance and family testing.

EPCAM Deletion Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn when ESR1 mutation testing is used in metastatic breast cancer, how plasma and tissue results are interpreted, and how activating variants can guide treatment after hormone therapy resistance.

ESR1 Mutation Test: Breast Cancer, Hormone Therapy Resistance, and Results

Learn how FGFR2 and FGFR3 genetic testing detects cancer mutations and fusions, what positive or negative results mean, and how findings may guide targeted therapy.

FGFR2 and FGFR3 Genetic Test: Cancer Mutations, Fusions, and Results

Understand FH genetic testing for hereditary leiomyomatosis and renal cell cancer, including who should test, result meanings, kidney surveillance, and family risk.

FH Genetic Test: Hereditary Leiomyomatosis, Renal Cell Cancer, and Results

Learn what FLCN genetic testing shows for Birt-Hogg-Dubé syndrome, including kidney cancer surveillance, lung cyst risks, result meanings, and family testing.

FLCN Genetic Test: Birt-Hogg-Dube Syndrome, Kidney Cancer, and Results

Learn how the FLT3 mutation test guides AML risk assessment, targeted treatment, transplant planning, relapse testing, and interpretation of ITD and TKD results.

FLT3 Mutation Test: AML, Leukemia Risk, and Treatment Results

Understand HER2 and ERBB2 testing in breast, gastric, lung, and other cancers, including IHC, ISH, mutations, targeted therapy, and result interpretation.

HER2/ERBB2 Test: Breast, Gastric, Lung Cancer, and Targeted Therapy Results

Learn how hereditary cancer genetic panels test multiple risk genes, who should be tested, what positive, negative, and VUS results mean, and how findings guide care.

Hereditary Cancer Genetic Panel Test: Cancer Risk Genes and Results

Learn how IDH1 and IDH2 mutation testing guides diagnosis and treatment in glioma, AML, and cholangiocarcinoma, including positive, negative, and targeted therapy results.

IDH1 and IDH2 Mutation Test: Brain Cancer, Leukemia, Cholangiocarcinoma, and Results

Learn how JAK2 mutation testing supports diagnosis of polycythemia vera, essential thrombocythemia, and myelofibrosis and how positive, negative, and low-level results are interpreted.

JAK2 Mutation Test: Myeloproliferative Neoplasm, Blood Cancer, and Results

Learn how KIT mutation testing guides GIST therapy, identifies selected melanoma targets, supports systemic mastocytosis diagnosis, and clarifies positive, negative, and low-level results.

KIT Mutation Test: GIST, Melanoma, Mast Cell Disease, and Results

Learn how KRAS mutation testing guides treatment in colorectal, lung, and pancreatic cancer and how to interpret G12C, other variants, negative results, and repeat testing.

KRAS Mutation Test: Colon, Lung, Pancreatic Cancer, and Results

1...858687...137 Page 86 of 137